US-based pharmaceutical major Eli Lilly has entered into a major agreement with Hong Kong biotech firm Insilico Medicine to develop new drugs using artificial intelligence, in a deal valued at up to $2 billion.
The partnership will focus on using Insilico’s AI technology to identify and develop promising drug candidates, especially oral medicines for various diseases. Under the agreement, Eli Lilly will gain exclusive global rights to further develop, manufacture, and commercialise any successful drugs emerging from the collaboration.
As part of the deal, Insilico Medicine will receive an upfront payment of around $115 million. In addition, the company is eligible for milestone payments linked to research progress, regulatory approvals, and commercial success. These could significantly increase the total value of the agreement over time.
This collaboration builds on an earlier partnership between the two companies and reflects a deeper commitment to AI-driven drug discovery. Both firms aim to combine Insilico’s advanced machine learning platforms with Eli Lilly’s experience in clinical development and global distribution.
Reports suggest that the agreement may include the development of a potential oral treatment for conditions such as diabetes, an area with high global demand. However, the broader focus remains on leveraging AI to streamline and speed up the drug discovery process.
Artificial intelligence is playing an increasingly important role in the pharmaceutical industry. By analysing large volumes of data and predicting how compounds will behave, AI can help identify viable drug candidates much faster than traditional research methods. This can reduce both the time and cost required to bring new medicines to market.
Also Read: Rupee breaches 95 against dollar